Neuroscience

AbbVie to Present at the Wolfe Research Healthcare Conference

Retrieved on: 
Wednesday, November 10, 2021

NORTH CHICAGO, Ill., Nov. 10, 2021 /PRNewswire/ --AbbVie (NYSE: ABBV) will participate in the Wolfe Research Healthcare Conference on Wednesday, November 17, 2021.

Key Points: 
  • NORTH CHICAGO, Ill., Nov. 10, 2021 /PRNewswire/ --AbbVie (NYSE: ABBV) will participate in the Wolfe Research Healthcare Conference on Wednesday, November 17, 2021.
  • Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present at 8:30 a.m. Central time.
  • A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com .
  • AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow.

Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences

Retrieved on: 
Tuesday, November 9, 2021

DUBLIN, Nov.9, 2021 /PRNewswire/ --Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will virtually participate in the following upcoming investor conferences:

Key Points: 
  • DUBLIN, Nov.9, 2021 /PRNewswire/ --Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will virtually participate in the following upcoming investor conferences:
    Jefferies London Healthcare Conference on Tuesday, November 16, 2021
    The presentation is scheduled for 11:20 11:55 a.m.
  • ET / 4:20 4:55 p.m. GMT
    Evercore ISI HealthCONx Conference on Tuesday, November 30, 2021
    The presentation is scheduled for 2:40 3:25 p.m.
  • ET / 7:40 8:25 p.m. GMT
    Jazz will virtually participate in both conferences and webcasts of the presentations will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharma.com .
  • Jazz Pharmaceuticals plc(NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families.

Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences

Retrieved on: 
Tuesday, November 9, 2021

DUBLIN, Nov. 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will virtually participate in the following upcoming investor conferences:

Key Points: 
  • DUBLIN, Nov.9, 2021 /PRNewswire/ --Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will virtually participate in the following upcoming investor conferences:
    Jefferies London Healthcare Conference on Tuesday, November 16, 2021
    The presentation is scheduled for 11:20 11:55 a.m.
  • ET / 4:20 4:55 p.m. GMT
    Evercore ISI HealthCONx Conference on Tuesday, November 30, 2021
    The presentation is scheduled for 2:40 3:25 p.m.
  • ET / 7:40 8:25 p.m. GMT
    Jazz will virtually participate in both conferences and webcasts of the presentations will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharma.com .
  • Jazz Pharmaceuticals plc(NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families.

Wave Neuroscience and Wounded Warrior Project Team Up on Operation Synchrony to Help Active-Duty Service Members and Veterans Improve Mental Wellness

Retrieved on: 
Tuesday, November 9, 2021

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    It is an honor to work with Wounded Warrior Project on this initiative, said Fred Walke, CEO of Wave Neuroscience.
  • Some of the most transformative results weve seen using personalized Braincare have been with military veterans and active-duty service members.
  • Combining the best of science, medicine and technology, Wave Neuroscience has innovated the future of mental and cognitive health, and it is personalized Braincare.
  • Its an extraordinary blessing and honor to collaborate with Wounded Warrior Project to help those who served within our military community.

Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China

Retrieved on: 
Tuesday, November 9, 2021

Karuna is evaluating KarXT in late-stage clinical trials for the treatment of schizophrenia and psychosis in Alzheimers disease.

Key Points: 
  • Karuna is evaluating KarXT in late-stage clinical trials for the treatment of schizophrenia and psychosis in Alzheimers disease.
  • Zai Lab will work with Karuna to design the optimal strategy to accelerate the development and regulatory timeline of KarXT in Greater China.
  • Karuna is also eligible to receive up to $72 million in sales milestones and low-double-digit to high-teens tiered royalties based on annual net sales of KarXT in Greater China.
  • Zai Lab will fund substantially all development, regulatory, and commercialization activities in Greater China.

Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States

Retrieved on: 
Tuesday, November 9, 2021

NEW HAVEN, Conn. and NEW YORK, Nov. 9, 2021 /PRNewswire/ --Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval.

Key Points: 
  • NEW HAVEN, Conn. and NEW YORK, Nov. 9, 2021 /PRNewswire/ --Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval.
  • Biohaven and Pfizer are entering into a collaboration and license agreement and related sublicense agreement pursuant to which Pfizer will acquire rights to commercialize rimegepant and zavegepant outside of the U.S. Biohaven will continue to lead research and development globally and Pfizer would execute commercialization globally, outside of the U.S.
  • As noted above, in connection with the transaction, Pfizer will make a $350 million investment in the common shares of Biohaven.
  • Biohaven and Pfizer global collaboration will be discussed on Biohaven 3Q Earnings Investor Call 8:00AM ET on November 9, 2021.

Zai Lab and Karuna Therapeutics Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China

Retrieved on: 
Tuesday, November 9, 2021

BOSTON and SHANGHAI and SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, and Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced their entry into an exclusive license agreement for the development, manufacturing, and commercialization of KarXT (xanomeline-trospium) in Greater China, including mainland China, Hong Kong, Macau, and Taiwan.

Key Points: 
  • Karuna is evaluating KarXT in late-stage clinical trials for the treatment of schizophrenia and psychosis in Alzheimers disease.
  • Zai Lab will work with Karuna to design the optimal strategy to accelerate the development and regulatory timeline of KarXT in Greater China.
  • Karuna is also eligible to receive up to $72 million in sales milestones and low-double-digit to high-teens tiered royalties based on annual net sales of KarXT in Greater China.
  • Zai Lab will fund substantially all development, regulatory, and commercialization activities in Greater China.

THE WEIZMANN INSTITUTE OF SCIENCE RECEIVES $50 MILLION (USD) FROM THE AZRIELI FOUNDATION TO HELP HUMANITY UNLOCK THE MYSTERIES OF THE BRAIN

Retrieved on: 
Tuesday, November 9, 2021

The Azrieli Foundation is a longstanding supporter of research at the Weizmann Institute, and this generous donation adds to its past philanthropic investments of nearly $30 million USD towards Weizmann research facilities and faculty and student fellowships.

Key Points: 
  • The Azrieli Foundation is a longstanding supporter of research at the Weizmann Institute, and this generous donation adds to its past philanthropic investments of nearly $30 million USD towards Weizmann research facilities and faculty and student fellowships.
  • The new Azrieli Institute for Brain and Neural Sciences embodies one of the Weizmann Institutes fundamental values interdisciplinary collaboration.
  • The Azrieli Foundations commitment to the Weizmann Institute is extraordinary and we are deeply grateful for their longstanding support and partnership.
  • This is how breakthroughs in brain research will happen, said Dr. Naomi Azrieli, Chair and CEO of the Azrieli Foundation.

Allen Institute Announces 2021 Next Generation Leaders

Retrieved on: 
Monday, November 8, 2021

SEATTLE, Nov. 8, 2021 /PRNewswire/ --The Allen Institute today announced six new Next Generation Leaders, members of a unique neuroscience advisory panel made up of early-career researchers.

Key Points: 
  • SEATTLE, Nov. 8, 2021 /PRNewswire/ --The Allen Institute today announced six new Next Generation Leaders, members of a unique neuroscience advisory panel made up of early-career researchers.
  • Now in its eighth year, the Next Generation Leaders Council advises neuroscience research efforts at the Allen Institute: the Allen Institute for Brain Science, the MindScope Program, and the newly launched Allen Institute for Neural Dynamics.
  • The newly appointed Next Generation Leaders are:
    The Allen Institute is an independent, 501(c)(3) nonprofit research organization founded by philanthropist and visionary, the late Paul G. Allen.
  • Its research institutes and programs include the Allen Institute for Brain Science, launched in 2003, the Allen Institute for Cell Science, launched in 2014, the Allen Institute for Immunology, launched in 2018, the MindScope Program, launched in 2020, and the Allen Institute for Neural Dynamics, launched in 2021.

Evolution Research Group, LLC Expands Clinical Development Capabilities and Adds Scientific Expertise

Retrieved on: 
Monday, November 8, 2021

ERG expanded its service offering to include specialized full-service CRO and rater training capabilities to satisfy increasing client demand, particularly in the early clinical development space.

Key Points: 
  • ERG expanded its service offering to include specialized full-service CRO and rater training capabilities to satisfy increasing client demand, particularly in the early clinical development space.
  • The expansion supports ERG's consistent strategy of continuously adding talent and services to further diversify within neuroscience and streamline clinical trial execution across all phases of development.
  • Ramirez has been a member of ERG's Scientific Leadership Team since its inception and along with its other members, including drug development experts Drs.
  • Evolution Research Group, LLC is a subsidiary of ERG Holding Company, which includes twenty wholly-owned and operated CRUs, an established network of affiliated clinical research sites, Lotus Clinical Research, LLC, a full-service CRO, and CNS Ratings, LLC, a rater training, surveillance and consulting company.